Gentian Diagnostics delivered double-digit revenue and profit growth in Q2 2024, driven by strong fCALⓇ turbo and Cystatin C sales, improved gross margin, and pipeline progress. New executive hires and positive clinical data support long-term growth ambitions.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.